Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1991 1
1993 2
1994 1
1995 1
1996 1
1999 1
2001 4
2002 2
2003 5
2004 2
2005 7
2006 4
2007 5
2008 8
2009 2
2010 5
2011 5
2012 10
2013 3
2014 7
2015 7
2016 8
2017 6
2018 3
2019 7
2020 5
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

110 results
Results by year
Filters applied: . Clear all
Page 1
Myasthenia gravis.
Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Gilhus NE, et al. Among authors: burns tm. Nat Rev Dis Primers. 2019 May 2;5(1):30. doi: 10.1038/s41572-019-0079-y. Nat Rev Dis Primers. 2019. PMID: 31048702 Review.
Myasthenia Gravis.
Gwathmey KG, Burns TM. Gwathmey KG, et al. Among authors: burns tm. Semin Neurol. 2015 Aug;35(4):327-39. doi: 10.1055/s-0035-1558975. Epub 2015 Oct 6. Semin Neurol. 2015. PMID: 26502757 Review.
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group. Howard JF Jr, et al. Among authors: burns tm. Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22. Neurology. 2019. PMID: 31118245 Free PMC article. Clinical Trial.
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Among authors: burns tm. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group. Muppidi S, et al. Among authors: burns tm. Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8. Muscle Nerve. 2019. PMID: 30767274 Free PMC article.
Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS.
Benatar M, Zhang L, Wang L, Granit V, Statland J, Barohn R, Swenson A, Ravits J, Jackson C, Burns TM, Trivedi J, Pioro EP, Caress J, Katz J, McCauley JL, Rademakers R, Malaspina A, Ostrow LW, Wuu J; CReATe Consortium. Benatar M, et al. Among authors: burns tm. Neurology. 2020 Jul 7;95(1):e59-e69. doi: 10.1212/WNL.0000000000009559. Epub 2020 May 8. Neurology. 2020. PMID: 32385188 Free PMC article.
Reply.
Burns TM, Smith GA. Burns TM, et al. Muscle Nerve. 2017 Jan;55(1):138-140. doi: 10.1002/mus.25436. Epub 2016 Nov 16. Muscle Nerve. 2017. PMID: 27756114 No abstract available.
Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.
Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi MT, Sams LA, Quan D, Ubogu E, Pearson B, Sharma A, Yankey JW, Uribe L, Shy M, Amato AA, Conwit R, O'Connor KC, Hafler DA, Cudkowicz ME, Barohn RJ; NeuroNEXT NN103 BeatMG Study Team. Nowak RJ, et al. Among authors: burns tm. Neurology. 2021 Dec 2;98(4):e376-89. doi: 10.1212/WNL.0000000000013121. Online ahead of print. Neurology. 2021. PMID: 34857535
Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF Jr, Howard D, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, LaBoy SM, Fellman MA, Greene SM, Pasnoor M, Burns TM. Hehir MK, et al. Among authors: burns tm. Neurology. 2017 Sep 5;89(10):1069-1077. doi: 10.1212/WNL.0000000000004341. Epub 2017 Aug 11. Neurology. 2017. PMID: 28801338
Vasculitic neuropathies.
Gwathmey KG, Burns TM, Collins MP, Dyck PJ. Gwathmey KG, et al. Among authors: burns tm. Lancet Neurol. 2014 Jan;13(1):67-82. doi: 10.1016/S1474-4422(13)70236-9. Lancet Neurol. 2014. PMID: 24331794 Review.
110 results